First experience of topical SDZ ASM 981 in children with atopic dermatitis.

@article{Harper2001FirstEO,
  title={First experience of topical SDZ ASM 981 in children with atopic dermatitis.},
  author={John I. Harper and Ad{\`e}le Green and Graham Scott and E Gruendl and Birgit Dorobek and Michael Cardno and Pascale Burtin},
  journal={The British journal of dermatology},
  year={2001},
  volume={144 4},
  pages={781-7}
}
BACKGROUND SDZ ASM 981 is a selective inhibitor of inflammatory cytokine release under development for the topical treatment of atopic dermatitis. OBJECTIVES This first paediatric study was designed to measure the systemic exposure to SDZ ASM 981 in young children with atopic dermatitis treated on extensive skin areas. METHODS Children 1-4 years of age referred to a tertiary care centre for their atopic dermatitis were treated twice daily for 3 weeks with 1% SDZ ASM 981 cream. SDZ ASM 981… CONTINUE READING